embody biosignals limited
embody biosignals limited Company Information
Company Number
09742798
Next Accounts
May 2025
Industry
Research and experimental development on biotechnology
Directors
Shareholders
christopher james
Group Structure
View All
Contact
Registered Address
northgate house, north gate new basford, nottingham, NG7 7BQ
Website
embody-biosignals.co.ukembody biosignals limited Estimated Valuation
Pomanda estimates the enterprise value of EMBODY BIOSIGNALS LIMITED at £34.5k based on a Turnover of £32.4k and 1.07x industry multiple (adjusted for size and gross margin).
embody biosignals limited Estimated Valuation
Pomanda estimates the enterprise value of EMBODY BIOSIGNALS LIMITED at £3.4k based on an EBITDA of £894 and a 3.77x industry multiple (adjusted for size and gross margin).
embody biosignals limited Estimated Valuation
Pomanda estimates the enterprise value of EMBODY BIOSIGNALS LIMITED at £0 based on Net Assets of £-3.5k and 1.89x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Embody Biosignals Limited Overview
Embody Biosignals Limited is a live company located in nottingham, NG7 7BQ with a Companies House number of 09742798. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in August 2015, it's largest shareholder is christopher james with a 100% stake. Embody Biosignals Limited is a young, micro sized company, Pomanda has estimated its turnover at £32.4k with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Embody Biosignals Limited Health Check
Pomanda's financial health check has awarded Embody Biosignals Limited a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 6 areas for improvement. Company Health Check FAQs
3 Strong
1 Regular
6 Weak
Size
annual sales of £32.4k, make it smaller than the average company (£3.3m)
- Embody Biosignals Limited
£3.3m - Industry AVG
Growth
3 year (CAGR) sales growth of 5%, show it is growing at a slower rate (12%)
- Embody Biosignals Limited
12% - Industry AVG
Production
with a gross margin of 25.5%, this company has a higher cost of product (54.5%)
- Embody Biosignals Limited
54.5% - Industry AVG
Profitability
an operating margin of 2.8% make it more profitable than the average company (-1.5%)
- Embody Biosignals Limited
-1.5% - Industry AVG
Employees
with 1 employees, this is below the industry average (43)
1 - Embody Biosignals Limited
43 - Industry AVG
Pay Structure
on an average salary of £75.3k, the company has an equivalent pay structure (£75.3k)
- Embody Biosignals Limited
£75.3k - Industry AVG
Efficiency
resulting in sales per employee of £32.4k, this is less efficient (£128.5k)
- Embody Biosignals Limited
£128.5k - Industry AVG
Debtor Days
it gets paid by customers after 42 days, this is earlier than average (53 days)
- Embody Biosignals Limited
53 days - Industry AVG
Creditor Days
its suppliers are paid after 106 days, this is slower than average (63 days)
- Embody Biosignals Limited
63 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Embody Biosignals Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Embody Biosignals Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 193.7%, this is a higher level of debt than the average (53.5%)
193.7% - Embody Biosignals Limited
53.5% - Industry AVG
EMBODY BIOSIGNALS LIMITED financials
Embody Biosignals Limited's latest turnover from August 2023 is estimated at £32.4 thousand and the company has net assets of -£3.5 thousand. According to their latest financial statements, Embody Biosignals Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||
| Other Income Or Grants | ||||||||
| Cost Of Sales | ||||||||
| Gross Profit | ||||||||
| Admin Expenses | ||||||||
| Operating Profit | ||||||||
| Interest Payable | ||||||||
| Interest Receivable | ||||||||
| Pre-Tax Profit | ||||||||
| Tax | ||||||||
| Profit After Tax | ||||||||
| Dividends Paid | ||||||||
| Retained Profit | ||||||||
| Employee Costs | ||||||||
| Number Of Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | |
|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 3,732 | 2,555 | 2,555 | 2,555 | 3,241 | 5,647 | 1,741 | 2 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9,880 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 3,732 | 2,555 | 2,555 | 2,555 | 3,241 | 5,647 | 1,741 | 9,882 |
| total assets | 3,732 | 2,555 | 2,555 | 2,555 | 3,241 | 5,647 | 1,741 | 9,882 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 7,035 | 6,553 | 6,383 | 6,213 | 6,384 | 2,718 | 50 | 9,880 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 7,035 | 6,553 | 6,383 | 6,213 | 6,384 | 2,718 | 50 | 9,880 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 194 | 170 | 170 | 120 | 480 | 600 | 1,689 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 194 | 170 | 170 | 120 | 480 | 600 | 1,689 | 0 |
| total liabilities | 7,229 | 6,723 | 6,553 | 6,333 | 6,864 | 3,318 | 1,739 | 9,880 |
| net assets | -3,497 | -4,168 | -3,998 | -3,778 | -3,623 | 2,329 | 2 | 2 |
| total shareholders funds | -3,497 | -4,168 | -3,998 | -3,778 | -3,623 | 2,329 | 2 | 2 |
| Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Profit | ||||||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | ||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 1,177 | 0 | 0 | -686 | -2,406 | 3,906 | 1,739 | 2 |
| Creditors | 482 | 170 | 170 | -171 | 3,666 | 2,668 | -9,830 | 9,880 |
| Accruals and Deferred Income | 24 | 0 | 50 | -360 | -120 | -1,089 | 1,689 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||||||
| Investing Activities | ||||||||
| capital expenditure | ||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||
| Financing Activities | ||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||
| interest | ||||||||
| cash flow from financing | ||||||||
| cash and cash equivalents | ||||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 | -9,880 | 9,880 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 | -9,880 | 9,880 |
embody biosignals limited Credit Report and Business Information
Embody Biosignals Limited Competitor Analysis
Perform a competitor analysis for embody biosignals limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in NG7 area or any other competitors across 12 key performance metrics.
embody biosignals limited Ownership
EMBODY BIOSIGNALS LIMITED group structure
Embody Biosignals Limited has no subsidiary companies.
Ultimate parent company
EMBODY BIOSIGNALS LIMITED
09742798
embody biosignals limited directors
Embody Biosignals Limited currently has 1 director, Dr Christopher James serving since Aug 2015.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Christopher James | United Kingdom | 56 years | Aug 2015 | - | Director |
P&L
August 2023turnover
32.4k
+35%
operating profit
894.7
0%
gross margin
25.5%
-17.56%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
August 2023net assets
-3.5k
-0.16%
total assets
3.7k
+0.46%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
embody biosignals limited company details
company number
09742798
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
August 2015
age
9
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
August 2023
previous names
N/A
accountant
RWB CA LIMITED
auditor
-
address
northgate house, north gate new basford, nottingham, NG7 7BQ
Bank
-
Legal Advisor
-
embody biosignals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to embody biosignals limited.
embody biosignals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for EMBODY BIOSIGNALS LIMITED. This can take several minutes, an email will notify you when this has completed.
embody biosignals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
